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Abstract
Background: The high rate of mortality due to malaria and the worldwide distribution of parasite
resistance to the commonly used antimalarial drugs chloroquine and pyrimethamine emphasize the
urgent need for the development of new antimalarial drugs. An alternative approach to the long
and uncertain process of designing and developing new compounds is to identify among the
armamentarium of drugs already approved for clinical treatment of various human diseases those
that may have strong antimalarial activity.
Methods: Proteasome inhibitor bortezomib (Velcade™: [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-
2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid), which has been approved for
treatment of patients with multiple myeloma, and a second boronate analog Z-Leu-Leu-Leu-
B(OH)2 (ZL3B), were tested against four different strains of P. falciparum (3D7, HB3, W2 and Dd2)
that are either sensitive or have different levels of resistance to the antimalarial drugs
pyrimethamine and chloroquine.
Results: Bortezomib and ZL3B are equally effective against drug-sensitive and -resistant parasites
and block intraerythrocytic development prior to DNA synthesis, but have no effect on parasite
egress or invasion.
Conclusion: The identification of bortezomib and its analog as potent antimalarial drugs will set
the stage for the advancement of this class of compounds, either alone or in combination therapy,
for treatment of malaria, and emphasize the need for large-scale screens to identify new
antimalarials within the library of clinically approved compounds.
Background
Malaria is caused by intraerythrocytic protozoan parasites
of the genus Plasmodium. It is responsible for more than
300 million clinical cases and over 2 million deaths annu-
ally [1]. Plasmodium falciparum, the organism that causes
the most lethal form of the disease, is becoming increas-
ingly resistant to almost all available drugs in the antima-
larial armamentarium [1]. New chemotherapeutic
strategies are therefore urgently needed to combat this dis-
ease.
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During its intraerythrocytic life cycle, a single P. falciparum
parasite undergoes multiple morphological and physio-
logical changes and multiplies to produce up to 36 new
daughter parasites in ~48 hours. Large-scale genomic and
proteomic analyses revealed a coordinated program of
gene and protein expression during parasite intraerythro-
cytic life cycle [2-7]. The first phase of this program occurs
during parasite transition from ring to trophzoite stage
and is marked by the induction of expression of enzymes
required for biosynthesis of proteins and membranes,
nutrient acquisition, and degradation of the host cyto-
plasm. The second phase occurs during transition from
trophozoite to early schizont and is manifested by the
induction of expression of enzymes required for biosyn-
thesis of ribonucleotides and deoxyribonucleotides and
for DNA replication. The third phase occurs during para-
site schizogony and is marked by the induction of subu-
nits of the proteasome. The last phase of this program
occurs during late schizogony and immediately after inva-
sion and becomes evident by the expression of specific
proteins required for host cell invasion [2]. The rise and
fall of expression of subsets of proteins during specific
stages of parasite intraerythrocytic life cycle suggest a coor-
dinated control of protein turnover during parasite devel-
opment. In eukaryotes, such regulation is controlled by
the proteasome.
Proteasomes are multicatalytic protease complexes whose
principle task is the selective degradation of proteins
within the cell. Although a fully intact proteasome has not
been isolated from P. falciparum, the sequencing of this
organism revealed a complete set of ORFs encoding
homologs of eukaryotic subunits of the proteasome [8-
10]. The expression of seven α and six β subunits of the
20S particle and 16 subunits of the 19S regulatory particle
of the putative P. falciparum proteasome suggest an impor-
tant role for this multicatalytic complex in parasite
intraerythrocytic cycle. Interestingly, this expression peaks
during parasite transition from developmental, structural
and metabolic functions to more specialized functions
important for the generation of new daughter parasites
capable of completing the cycle and invading new host
cells [5,6]. This suggests that the parasite proteasome
could play an important role in protein turnover and par-
asite replication. Accordingly, the proteasome inhibitor
lactacystin was found to inhibit erythrocytic schizogony
of P. falciparum prior, but not subsequent, to DNA synthe-
sis and parasite multiplication [11].
Several studies have highlighted the importance of protea-
some inhibition as a possible approach for the treatment
of cancer and parasitic diseases [11-13]. Lindenthal and
colleagues showed that the boronate analog MLN-273
blocks the exoerythrocytic development of P. berghei and
the intraerythrocytic development of P. falciparum [12].
Here we provide data indicating that the proteasome
inhibitor and analog of MLN-273, bortezomib (Velcade™:
[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinyl-
carbonyl) amino]propyl]amino]butyl] boronic acid),
which has been approved for treatment of patients with
multiple myeloma, and a second boronate analog Z-Leu-
Leu-Leu-B(OH)2 (ZL3B), which was found to be highly
toxic to trypanosomatid parasites (IC50 of 0.32 nM in cul-
ture; [14]) are potent inhibitors of P. falciparum.
Bortezomib was the first proteasome inhibitor shown to
have anti-cancer activity and to induce a marked and
durable response in patients with multiple myeloma in
clinical trials [15]. We have tested bortezomib and ZL3B in
different strains of P. falciparum including strains that are
resistant to pyrimethamine and chloroquine. We found
that both compounds are equally effective against drug-
sensitive and -resistant parasites with inhibitory concen-
trations in the low nanomolar range. The compounds
block intraerythrocytic development prior to DNA synthe-
sis, but had no effect on parasite egress or invasion.
Methods
Strains
The clones 3D7, HB3, Dd2, and W2 of P. falciparum used
in this study were obtained from the Malaria Research and
Reference Reagent Resource Center (MR4).
Cell Culture and Materials
Parasites were cultured by the method of Trager and
Jensen [16] by using a gas mixture of 3% O2, 3% CO2, and
94% N2. RPMI medium 1640 was supplemented with 30
mg/liter hypoxanthine (Sigma), 25 mM Hepes (Sigma),
0.225% NaHCO3 (Sigma), 0.5% Albumax I (Life Technol-
ogies, Grand Island, NY), and 10 μg/ml gentamycin (Life
Technologies). Bortezomib was purchased from the Uni-
versity of Connecticut Health Center Pharmacy. ZL3B was
purchased from Boston Biochemical Inc. (Cat# I-120).
Parasite synchronization was obtained with three succes-
sive 5% sorbitol treatments [17]. To determine visually
the stage of the parasite life cycle, fixed smears of the P. fal-
ciparum-infected erythrocytes were stained with Giemsa
stain and analyzed by bright-field microscopy.
Hypoxanthine incorporation assay
The susceptibility of parasites to different compounds was
assessed by tritiated hypoxanthine uptake as described by
Desjardins and colleagues [18]. Briefly, infected erythro-
cytes (2% hematocrit, 3% rings) were washed and incu-
bated with the appropriate drugs at the listed
concentrations in hypoxanthine-free media for 48 hours.
200 μL of the mixture was then added to a 96 well plate
with 3H-hypoxanthine at a concentration of 0.5 μCi/well.
Following an incubation of 24 hours, the cells were
washed on an ultrafilter and radioactivity was countedBMC Clinical Pharmacology 2007, 7:13 http://www.biomedcentral.com/1472-6904/7/13
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using a scintillation counter. IC50's are represented in nM.
Values are means ± standard deviation of three independ-
ent experiments each performed in triplicate. These exper-
iments were performed at least three times with similar
results.
Results and Discussion
ZL3B and bortezomib inhibit the P. falciparum 
intraerythrocytic cycle
The cell permeable peptide boronate Z-Leu-Leu-Leu-
B(OH)2 (ZL3B) (Fig. 1A) is a specific and potent proteas-
ome inhibitor that blocks the growth of the bloodstream
form of the protozoan parasite Trypanosoma brucei with a
50% inhibitory concentration (IC50) of 0.32 nM in culture
[14]. In order to examine the antimalarial activity of ZL3B,
we have tested the effect of increasing concentrations of
this compound up to 200 nM on the intraerythrocytic life
cycle of P. falciparum in culture by following the incorpo-
ration of radiolabeled hypoxanthine into parasite nucleic
acids. The study was performed with four different strains
of P. falciparum (3D7, HB3, W2 and Dd2) that are either
sensitive or have different levels of resistance to the anti-
malarial drugs pyrimethamine and chloroquine (Fig.
1C–F and Table 1). ZL3B was found to inhibit parasite
Structures of ZL3B (A) and bortezomib (B) Figure 1
Structures of ZL3B (A) and bortezomib (B). Inhibition of 3D7 (closed squares), HB3 (open squares), W2 (open circles), and 
Dd2 (open triangles) parasite clones as a function of ZL3B (C), bortezomib (D), pyrimethamine (E) and chloroquine (F) con-
centrations. The clones of P. falciparum used in this study were obtained from the Malaria Research and Reference Reagent 
Resource Center (MR4). IC50's are represented in nM. Values are means ± standard deviation of three independent experi-
ments each performed in triplicate.
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proliferation with an IC50 values between 34 and 45 nM.
Due to the strong antimalarial activity of ZL3B, we specu-
lated that the ZL3B analog and clinically approved peptide
boronate, bortezomib (Fig. 1B) might have a similar anti-
malarial activity. Bortezomib is a boronic acid dipeptide
and a reversible inhibitor of the chymotrypsin-like activity
of the 20S proteasome [15]. It strongly and selectively
inhibits the proteasome, has substantial cytotoxicity
against a broad range of human tumor cells and has
shown excellent anti-tumour activity in preclinical and
clinical trials [15]. Bortezomib was approved by the U.S.
Food and Drug Administration and the European com-
mission for the treatment of advanced multiple myeloma,
and more recently, it received a fast track status for
relapsed and refractory mantle cell lymphoma [13]. We
first analyzed the antimalarial activity of bortezomib by
using the hypoxanthine assay and found that the drug
inhibited proliferation of P. falciparum 3D7, HB3, W2 and
Dd2 strains with IC50 values ranging between 31 and 43
nM (Fig. 1D and Table 1). As a control, we confirmed the
IC50 of chloroquine and pyrimethamine in the four strains
(Fig. 1E and 1F, and Table 1). As expected, strain 3D7 was
sensitive to both compounds with IC50 of 6 ± 0.2 and 5 ±
1.1 nM, respectively; strain HB3 was sensitive to chloro-
quine (IC50: 8 ± 1.4 nM) and resistant to pyrimethamine
(IC50: 500 ± 45 nM); strain W2 was moderately resistant
to chloroquine (IC50: 90 ± 3.7 nM) and highly resistant to
pyrimethamine (IC50: 1.5 ± 0.006 μM), and Dd2 was
highly resistant to both chloroquine (IC50: 300 ± 21 nM)
and pyrimethamine (IC50: 2.5 ± 0.097 μM). To further
confirm the inhibitory effects of bortezomib and ZL3B on
P. falciparum growth, we employed the pLDH colorimetric
assay, which measures the production of parasite specific
lactate dehydrogenase activity [19-21]. Consistent with
the results of the hypoxanthine incorporation assay, both
compounds were found to inhibit equally well chloro-
quine- and pyrimenthamine- sensitive and resistant
strains (not shown). Noteworthy, these studies were also
consistent with the finding that another boronic deriva-
tive, MLN-273, inhibits the intraerythrocytic development
of P. falciparum [12].
Bortezomib and ZL3B antimalarial activities occur prior to 
DNA synthesis
To determine the developmental stage during which bort-
ezomib and ZL3B exert their antimalarial effects, P. falci-
parum  cultures were synchronized and the proteasome
inhibitors were added to the culture medium at different
times following parasite invasion and a final concentra-
tion of 100 nM. Culture samples were collected every 6
hours and parasite intraerythrocytic developmental pro-
gression was monitored by Giemsa staining and light
microscopic analysis (Fig. 2A). As a control, an untreated
culture of P. falciparum-infected erythrocytes was moni-
tored. In the absence of bortezomib or ZL3B, the parasite
displayed a normal cycle progression from rings to tro-
phozoites, trophozoites to schizonts and schizonts to
rings in approximately 44 hours (Fig. 2A). Addition of
bortezomib or ZL3B during the ring (8, 16 h post-inva-
sion) or early trophozoite (24 h post-invasion) stages
resulted in a complete blockage of developmental pro-
gression and subsequent death of the parasites. Treatment
with these compounds during the late trophozoite stage
(32 h post-invasion) only partially blocked parasite pro-
gression (Fig. 2B). On the other hand, treatment during
the schizont stage (40 h post-invasion) had no effect on
parasite progression (Fig. 2A). This stage-specific inhibi-
tory effect of bortezomib and ZL3B was quantified by
(A) Stage specific inhibition of P. falciparum (3D7) parasite by  ZL3B and bortezomib Figure 2
(A) Stage specific inhibition of P. falciparum (3D7) parasite by 
ZL3B and bortezomib. Highly synchronized cultures of the 
parasites were grown in the absence or presence of 100 nM 
of ZL3B or bortezomib, stained by Giemsa stain, and analyzed 
by light microscopy.(B) Estimated number of daughter rings 
formed 48 h following parasite (3D7) invasion of host eryth-
rocytes in the absence (U) or presence of ZL3B (Z) or borte-
zomib (B). Drugs were applied at 8, 16, 24, 32, 40 and 48 h 
following parasite invasion.
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Table 1: 50% Inhibitory concentrations IC50 (nM) of ZL3 B, 
bortezomib, chloroquine and pyrimethamine in P. falciparum 
strains
3D7 HB3 W2 Dd2
ZL3B 40 ± 12 45 ± 5.8 34 ± 3.9 40 ± 11.1
Bortezomib 31 ± 1.8 31 ± 2.7 43 ± 4 37 ± 5.1
Chloroquine 6 ± 0.2 8 ± 1.4 90 ± 3.7 300 ± 21
Pyrimethamine 5 ± 1.1 500 ± 45 1500 ± 5.8 2500 ± 97BMC Clinical Pharmacology 2007, 7:13 http://www.biomedcentral.com/1472-6904/7/13
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counting the number of rings that developed 48 hours
post-invasion in the absence or presence of the com-
pounds. Consistent with the previous analysis, no rings
could be detected from cultures treated with bortezomib
or ZL3B 8, 16 or 24 h post-invasion. In contrast, treatment
with these compounds 32 h post-invasion reduced the
number of rings in comparison to untreated parasites by
40% only (Fig. 2B) and treatment 40 h post-invasion was
completely ineffective (not shown). Together these data
suggest that these compounds inhibit parasite develop-
ment and multiplication and have a lesser effect on the
release of merozoites from the infected erythrocytes or on
the invasion of new red blood cells by the released mero-
zoites. Although a direct effect of these compounds on the
proteasome has not been investigated, our data along
with the known mode of action of these compounds in
other cell lines suggest an important role for the P. falci-
parum proteasome in parasite development and DNA syn-
thesis.
The recommended adult dose of bortezomib for treat-
ment of myeloma is 1.3 mg/m2; and in children the com-
pound is used at a dose of 1.2 mg/m2 [22-24]. The mean
peak plasma concentration (Cmax) determined 5 min
after drug administration at doses between 1.3 and 1.7
mg/m2 was 63 ± 16 ng/ml and the mean area under the
concentration-time curve extrapolated to infinity
(AUCinf) was 27 h ng/ml [23]. These values are 2 to 4-fold
the IC50 observed with bortezomib in P. falciparum. In vivo
studies to determine the dose and tolerability of this com-
pound for treatment of malaria are warranted.
Conclusion
Our studies demonstrate that two boronates, ZL3B and its
clinically-approved analog bortezomib, are potent inhib-
itors of the intraerythrocytic cycle of both drug-sensitive
and resistant P. falciparum strains. These findings will set
the stage for the evaluation of this new class of com-
pounds for treatment and/or prophylaxis of falciparum
malaria. Furthermore, our studies set the stage for large-
scale screens to identify new antimalarials among clini-
cally approved drugs. This approach could shorten the
lengthy and expensive process of designing, developing
and testing the potency, efficacy and safety of new drugs.
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